TransMedics Group, Inc. (TMDX) Q1 2022 Earnings Results

TransMedics Group, Inc. Misses on EPS — Stock Down 0.59%

TransMedics reported a loss that was slightly worse than expectations, which contributed to a modest decline in the stock price. The lack of revenue details and guidance may leave investors cautious. Management's focus on long-term growth suggests they are prioritizing future potential over immediate results.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.38	N/A	-8.57%

Management

Management commentary

Tone: Defensive

Management acknowledged the difficulties faced in the quarter. They remain committed to their strategic goals but did not provide specific guidance.

Management highlighted ongoing challenges in the market.

They emphasized a focus on long-term growth despite current setbacks.

TransMedics Group, Inc. Misses on EPS — Stock Down 0.59%

Key numbers

Management commentary

TransMedics Group, Inc.

More earnings this week

TransMedics Group, Inc. Misses on EPS — Stock Down 0.59%

Key numbers

Management commentary